X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4165) 4165
glucagon-like peptide-1 (3376) 3376
animals (2690) 2690
male (2477) 2477
endocrinology & metabolism (2271) 2271
diabetes (1876) 1876
diabetes mellitus, type 2 - drug therapy (1855) 1855
glucagon (1687) 1687
type 2 diabetes (1670) 1670
female (1593) 1593
glucose (1510) 1510
insulin (1460) 1460
hypoglycemic agents - therapeutic use (1349) 1349
glucagon-like peptide 1 (1275) 1275
peptides (1265) 1265
liraglutide (1264) 1264
glp-1 (1180) 1180
glucagon-like peptide 1 - analogs & derivatives (1165) 1165
middle aged (1061) 1061
mice (1050) 1050
rats (973) 973
obesity (938) 938
pharmacology & pharmacy (929) 929
adult (924) 924
diabetes mellitus (901) 901
blood glucose - metabolism (832) 832
glycemic control (781) 781
glucagon-like peptide-1 receptor (764) 764
glucagon-like peptide 1 - therapeutic use (742) 742
exenatide (734) 734
glucagon-like peptide 1 - metabolism (718) 718
hypoglycemic agents - pharmacology (681) 681
research (658) 658
analysis (642) 642
insulin - metabolism (627) 627
aged (616) 616
glucagon-like peptide 1 - pharmacology (601) 601
treatment outcome (599) 599
diabetes mellitus, type 2 - blood (597) 597
physiological aspects (568) 568
hypoglycemic agents - administration & dosage (565) 565
dextrose (563) 563
secretion (560) 560
blood glucose - drug effects (550) 550
diabetes mellitus, type 2 - metabolism (550) 550
insulin resistance (548) 548
care and treatment (546) 546
internal medicine (544) 544
metabolism (544) 544
peptides - pharmacology (533) 533
digestive, oral, and skin physiology (522) 522
rodents (517) 517
insulin - blood (516) 516
medicine & public health (510) 510
food-intake (501) 501
metformin (498) 498
hypoglycemic agents - adverse effects (493) 493
double-blind (491) 491
glucagon-like peptide 1 - blood (491) 491
exendin-4 (487) 487
peptides - therapeutic use (487) 487
abridged index medicus (483) 483
health aspects (481) 481
physiology (477) 477
insulin secretion (469) 469
endocrine system (457) 457
beta-cell function (456) 456
hypoglycemic agents (447) 447
drug therapy (440) 440
body weight (436) 436
diabetes therapy (432) 432
receptors, glucagon - agonists (424) 424
dipeptidyl-peptidase iv inhibitors - therapeutic use (422) 422
risk factors (419) 419
expression (418) 418
biochemistry & molecular biology (416) 416
hyperglycemia (415) 415
receptor (400) 400
insulin-secretion (393) 393
type-2 diabetes-mellitus (392) 392
nutrition & dietetics (387) 387
glucose metabolism (385) 385
venoms - pharmacology (380) 380
clinical trials (379) 379
hormones, hormone substitutes, and hormone antagonists (376) 376
venoms - therapeutic use (371) 371
mice, inbred c57bl (366) 366
proteins (364) 364
hormones (361) 361
review (356) 356
safety (353) 353
glucagon-like peptide-1 receptor - agonists (352) 352
glucagon-like peptide 1 - administration & dosage (350) 350
incretin (350) 350
appetite (347) 347
double-blind method (344) 344
gastric-inhibitory polypeptide (338) 338
rats, sprague-dawley (336) 336
medicine, research & experimental (334) 334
drug therapy, combination (331) 331
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6521) 6521
German (43) 43
Japanese (35) 35
Spanish (21) 21
French (19) 19
Chinese (18) 18
Italian (10) 10
Danish (8) 8
Czech (7) 7
Polish (7) 7
Hungarian (6) 6
Korean (5) 5
Portuguese (5) 5
Russian (4) 4
Swedish (3) 3
Dutch (2) 2
Bosnian (1) 1
Croatian (1) 1
Norwegian (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the American Chemical Society, ISSN 0002-7863, 09/2014, Volume 136, Issue 37, pp. 12848 - 12851
... residues with conformationally constrained β-amino acid residues. This backbone-modification approach may be useful for developing stabilized analogues of other peptide... 
DESIGN | INHIBITION | GLUCAGON-LIKE PEPTIDE-1 | EXENDIN-4 | STABILITY | PROTEIN-PROTEIN INTERACTIONS | COUPLED RECEPTORS | AMINO-ACID RESIDUES | AGONISTS | CHEMISTRY, MULTIDISCIPLINARY | HELIX MIMICRY | Type 2 diabetes | Care and treatment | Peptides | Glucagon | Analysis | Residues | Surgical implants | Biomedical materials | In vivo testing | Surface chemistry | In vivo tests | Biocompatibility | Strategy | Communication
Journal Article
Atherosclerosis, ISSN 0021-9150, 2012, Volume 221, Issue 2, pp. 375 - 382
.... ► In summary, liraglutide can reduce oxidative stress and inflammation in HUVEC. Glucagon-like peptide 1 (GLP-1... 
Cardiovascular | Oxidative stress | NF-κB | Endothelial cell | Inflammation | Apoptosis | CHRONIC HEART-FAILURE | TRANSLOCATION | PROTEIN-KINASE-C | PENTRAXIN 3 | ACTIVATION | CARDIAC & CARDIOVASCULAR SYSTEMS | IN-VITRO | NF-kappa B | ACUTE MYOCARDIAL-INFARCTION | DEGRADATION | PERIPHERAL VASCULAR DISEASE | DYSFUNCTION | VASCULAR NAD(P)H OXIDASE | Tumor Necrosis Factor-alpha - metabolism | Phosphorylation | Reactive Oxygen Species - metabolism | Human Umbilical Vein Endothelial Cells - metabolism | Membrane Glycoproteins - metabolism | Protein Kinase C-alpha - metabolism | Apoptosis - drug effects | Humans | NADPH Oxidases - metabolism | Human Umbilical Vein Endothelial Cells - immunology | NF-kappa B - metabolism | I-kappa B Proteins - metabolism | Dose-Response Relationship, Drug | C-Reactive Protein - metabolism | Transfection | I-kappa B Kinase - metabolism | Time Factors | Inflammation Mediators - metabolism | Superoxide Dismutase - metabolism | Recombinant Proteins - metabolism | Glutathione Peroxidase - metabolism | Human Umbilical Vein Endothelial Cells - drug effects | Anti-Inflammatory Agents - pharmacology | Glucagon-Like Peptide 1 - analogs & derivatives | Cells, Cultured | Glucagon-Like Peptide 1 - pharmacology | Antioxidants - pharmacology | NADPH Oxidase 2 | Protein Transport | Catalase - metabolism | NF-kappa B - genetics | Signal Transduction - drug effects | Serum Amyloid P-Component - metabolism | Oxidative Stress - drug effects | Liraglutide
Journal Article
Psychopharmacology (Berlin, Germany), ISSN 1432-2072, 2018, Volume 236, Issue 2, pp. 603 - 611
Journal Article
PloS one, ISSN 1932-6203, 07/2013, Volume 8, Issue 7, p. e69010
Journal Article
Journal of medicinal chemistry, ISSN 0022-2623, 09/2015, Volume 58, Issue 18, pp. 7370 - 7380
Journal Article
Journal Article
PloS one, ISSN 1932-6203, 04/2013, Volume 8, Issue 4, p. e61965
Journal Article
Diabetes, obesity & metabolism, ISSN 1462-8902, 01/2018, Volume 20, Issue 1, pp. 60 - 68
...‐hyperglycaemic effects of a glucagon‐like peptide‐1 (GLP‐1) agonist (liraglutide). Methods The acute insulinotropic effect of ZP4165 was investigated in rats during an oral glucose tolerance test. The long... 
glycaemic control | GLP‐1 | diabetes | HbA1c | obesity | GIP | GLP-1 | RAT | AMIDE | PEPTIDE | GLUCOSE | ENDOCRINOLOGY & METABOLISM | DEPENDENT INSULINOTROPIC POLYPEPTIDE | FAT-FED MICE | GASTRIC-INHIBITORY POLYPEPTIDE | RECEPTORS | AGONIST | Anti-Obesity Agents - blood | Gastric Inhibitory Polypeptide - pharmacokinetics | Obesity - drug therapy | Gastric Inhibitory Polypeptide - therapeutic use | Humans | Half-Life | Male | Diabetes Mellitus, Type 2 - metabolism | Weight Loss - drug effects | Receptors, Gastrointestinal Hormone - metabolism | Obesity - blood | Receptors, Gastrointestinal Hormone - agonists | Anti-Obesity Agents - therapeutic use | Glucagon-Like Peptide-1 Receptor - genetics | Hypoglycemic Agents - blood | Glucagon-Like Peptide-1 Receptor - metabolism | Anti-Obesity Agents - pharmacokinetics | Liraglutide - pharmacology | Mice, Mutant Strains | Drug Design | HEK293 Cells | Incretins - pharmacology | Drug Therapy, Combination | Gastric Inhibitory Polypeptide - pharmacology | Hypoglycemic Agents - therapeutic use | Receptors, Glucagon - genetics | Recombinant Proteins - metabolism | Hyperglycemia - prevention & control | Hypoglycemic Agents - pharmacokinetics | Mice, Inbred C57BL | Receptors, Glucagon - metabolism | Recombinant Proteins - chemistry | Recombinant Proteins - genetics | Rats, Sprague-Dawley | Hypoglycemic Agents - pharmacology | Obesity - metabolism | Diabetes Mellitus, Type 2 - blood | Animals | Liraglutide - therapeutic use | Receptors, Gastrointestinal Hormone - genetics | Incretins - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Anti-Obesity Agents - pharmacology | Gastric Inhibitory Polypeptide - analogs & derivatives | Glucagon-Like Peptide-1 Receptor - agonists | Type 2 diabetes | Obesity | Control | Glucagon | Rodents | Body weight | Weight loss | Glycosylated hemoglobin | Glucose | Glucose tolerance tests | Dextrose | Diabetes mellitus | Body weight loss | GIP protein | Studies | Glucose tolerance | Weight control | Hemoglobin | Diabetes | Glucagon-like peptide 1 | Long-term effects
Journal Article